Sites of action of ONTOZRY® and selected other ASMs. Adapted from Löscher et al, 2021
The precise mechanism of action by which ONTOZRY® exercises its therapeutic effects in patients with focal-onset seizures is unknown.1-3
Prescribing Information and Adverse Event Reporting
ASM = anti-seizure medication, GABA = gamma-aminobutyric acid.
Reference:
1. ONTOZRY® Summary of product characteristics. 2. Löscher W, et al. Epilepsia. 2021;62:596-614. 3. Schmidt D, Schachter SC. BMJ. 2014;348;g2546.
UK11749P | April 2022
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should be reported to Arvelle Therapeutics UK on 02034889643 or at UKIReporting@angelinipharma.com.
This site is published and funded by Arvelle Therapeutics UK which is solely responsible for its content. This site is intended exclusively for UK healthcare professionals.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should be reported to Arvelle Therapeutics UK on 02034889643 or at UKIReporting@angelinipharma.com.
This site is published and funded by Arvelle Therapeutics UK which is solely responsible for its content. This site is intended exclusively for UK healthcare professionals.
Listen to leading experts discuss key evolving topics in the field of epilepsy through a focused webinar series, podcasts and more.
UK Website
